Dayvigo Accelerated Titration: How to Titrate Lemborexant Safely

Lemborexant, sold under the brand name Dayvigo, is a dual orexin receptor antagonist (DORA) approved by the FDA for insomnia involving difficulty with sleep onset, sleep maintenance, or both. It comes as oral tablets in two strengths only, 5 mg and 10 mg, taken once nightly. This article does not cover the related but distinct drug suvorexant (Belsomra), except for comparison, and it does not cover injectable or compounded formulations, because none exist for lemborexant.

What is established, what is not

Established from the FDA label: lemborexant is started at 5 mg for every adult patient regardless of age or sex, may be increased to a maximum of 10 mg if 5 mg is tolerated but insufficiently effective, has no intermediate dose, and requires dose capping or contraindication in the presence of moderate-to-strong CYP3A inhibitors or moderate-to-severe hepatic impairment. Plausible but not established by the label itself: the widely used clinical practice of waiting roughly 7 to 14 nights before escalating. That interval reflects common sleep-medicine practice and the drug's pharmacokinetics (time to reach steady state), not a labeled requirement. Not established from the materials available for this article: specific numeric effect sizes and adverse-event rates from the pivotal trial program, and specific quoted guideline language on combining orexin antagonists with other CNS depressants. Those figures appeared in an earlier draft of this page attached to citations that could not be verified against the primary literature for this revision, so they have been removed or generalized here pending confirmation by a clinician reviewer with direct access to the published trial reports.

What the FDA label actually permits

The Dayvigo prescribing information directs prescribers to start at 5 mg taken orally once per night, within five minutes of getting into bed, with at least seven hours of intended sleep time remaining (FDA label, 2019). If 5 mg is tolerated but does not adequately control symptoms, the dose can be raised to 10 mg. The label does not specify a minimum number of nights on 5 mg before that increase, which leaves the timing to clinical judgment rather than a fixed schedule.

Two constraints are worth stating plainly. First, 10 mg is never a starting dose; every patient begins at 5 mg. Second, there is no 7.5 mg tablet and tablets should not be split, so the choice at any decision point is binary: stay at 5 mg or move to the full 10 mg.

CYP3A interactions can remove escalation as an option

Moderate CYP3A inhibitors (the label lists examples such as fluconazole and verapamil) cap the maximum recommended dose at 5 mg. Strong CYP3A inhibitors make lemborexant contraindicated altogether (FDA label, 2019). Anyone planning a titration conversation should check the patient's full medication list for these interactions before discussing dose increases, because for some patients 5 mg is the ceiling regardless of symptom response.

Hepatic impairment also limits the ceiling

The label does not require dose adjustment for mild hepatic impairment (Child-Pugh A). Moderate hepatic impairment (Child-Pugh B) lowers the maximum recommended dose to 5 mg, and severe hepatic impairment is a contraindication (FDA label, 2019). Liver status should be known before any escalation plan is made.

What the pivotal trial evidence shows, and what it does not

A phase 3, randomized, double-blind, placebo-controlled trial (commonly referred to in the literature as SUNRISE-1) enrolled adults aged 55 and older with insomnia disorder and compared lemborexant 5 mg and 10 mg against placebo, using polysomnography as an objective outcome measure. Published reporting on this trial describes statistically significant improvement at both doses on measures of sleep onset and sleep maintenance, with a numerically larger effect at 10 mg than at 5 mg. This article does not restate the exact minute-by-minute effect sizes or adverse-event percentages that circulated in an earlier draft, because those figures were attached to a citation that could not be confirmed as the correct source for this revision. A clinician reviewer with direct access to the peer-reviewed publication should verify and reinsert precise numbers before this page is published.

What the trial design does answer: both doses work compared with placebo, and 10 mg appears to work somewhat better on objective sleep measures in adults 55 and older. What it does not answer: it was not a titration study. Participants were randomized directly to a fixed dose rather than starting at 5 mg and escalating, so it cannot by itself validate any particular escalation timeline, including a 7-to-14-night window.

How clinicians typically approach the escalation decision

Absent a mandated schedule, real-world titration is shaped by pharmacokinetics and patient-reported response rather than a rigid protocol.

Lemborexant reaches peak plasma concentration in roughly 1 to 3 hours and has a half-life of approximately 17 to 19 hours, reaching steady-state plasma levels within about 4 to 5 days of nightly dosing, per the FDA label. In practice, this means a patient who has taken 5 mg nightly for about a week has already had several days at steady-state exposure, which is enough time to judge both effect and next-day tolerability at that dose. This is the pharmacologic basis, not a label requirement, for the common practice of reassessing after roughly one to two weeks before deciding whether to move to 10 mg.

Decisions in practice usually rest on a sleep diary and, often, a validated instrument such as the Insomnia Severity Index, rather than repeat polysomnography, which is rarely performed outside research settings. Exact numeric thresholds for "still symptomatic enough to escalate" vary by clinician and are a matter of judgment rather than a labeled cutoff; a reader should not treat any specific score as a fixed rule without discussing it with their prescriber.

Clinician conversation and monitoring framework

This framework is designed to structure a discussion between a patient and prescriber about whether and when to move from 5 mg to 10 mg. It reflects label boundaries plus common clinical practice; it is not a mandated protocol and does not substitute for individualized care.

Checkpoint 1: Before starting 5 mg

• Confirm no strong CYP3A inhibitor use (contraindicated) and no severe hepatic impairment (contraindicated).
• Note any moderate CYP3A inhibitor use or moderate hepatic impairment; if present, flag that 5 mg will likely be the ceiling regardless of response.
• Confirm the patient can commit to at least seven hours of sleep time and can take the dose within five minutes of getting into bed, away from a heavy meal.

Checkpoint 2: Days 1 to 7 on 5 mg

• Track sleep diary data: time to fall asleep, number and length of awakenings, total sleep time, next-day alertness.
• Watch for early adverse effects: morning grogginess, dizziness, unusual dreams, or any episode of waking unable to move (sleep paralysis).
• Stop-and-reassess condition: if the patient reports significant next-day sedation, impaired driving-relevant alertness, or any sleep paralysis or hallucination episode, do not escalate at the next checkpoint. Address timing, food intake, and interacting medications first.

Checkpoint 3: Around day 7 to 14 (typical, not mandated)

• Ask two binary questions. Did the patient tolerate 5 mg without meaningful next-day impairment? Does the patient still have clinically significant insomnia symptoms despite adherence?
• If both answers point toward inadequate benefit with good tolerability, escalation to 10 mg is a reasonable clinical discussion.
• If tolerability is the problem, escalation is not appropriate; the priority is identifying the cause (timing, food, interacting drugs, or an intolerance to the drug itself).
• If the patient is on a CYP3A inhibitor that caps the dose at 5 mg, or has moderate hepatic impairment, this checkpoint does not apply; there is no escalation option.

Checkpoint 4: If escalating to 10 mg

• Switch directly; there is no intermediate dose and tablets should not be split.
• Repeat the driving and machinery caution at the point of escalation, not only at treatment start, since somnolence risk is described in the label as dose-related.
• Reassess again after roughly one week on 10 mg for both symptom control and next-day effects.

Checkpoint 5: If 10 mg is insufficient

• Ten milligrams is the labeled ceiling; there is no higher approved dose to move to.
• Reassess the insomnia diagnosis and screen for untreated comorbid conditions such as obstructive sleep apnea or restless legs syndrome.
• Discuss cognitive behavioral therapy for insomnia (CBT-I) as a first-line or adjunctive option, consistent with the general treatment principle that behavioral therapy is preferred as an initial approach for chronic insomnia in guideline-based care; the specific guideline language should be verified against the current published version before being cited directly on this page.

When to seek urgent evaluation rather than adjust the dose:

• New confusion, difficulty breathing, or signs of a severe allergic reaction after any dose.
• Sleepwalking or complex sleep behaviors (eating, driving, or other activity while not fully awake), which warrant stopping the medication and contacting the prescriber promptly rather than waiting for the next scheduled checkpoint.
• Any suicidal thinking, which warrants immediate contact with a clinician or emergency services regardless of what dose the patient is on.

Lemborexant compared with suvorexant on titration structure

Suvorexant (Belsomra) is available in 5 mg, 10 mg, 15 mg, and 20 mg tablets, with a recommended starting dose of 10 mg and a maximum of 20 mg (FDA label, 2014). That four-tier structure allows more gradual, stepwise increases. Lemborexant's two-tier structure (5 mg or 10 mg only) makes the escalation decision a single binary choice rather than a multi-step process. Neither structure is inherently safer; they simply reflect different dose-response curves established in each drug's own trial program, and switching between the two drugs is a distinct clinical decision that this page does not address.

Special situations worth flagging to a prescriber

Older adults. The pivotal trial referenced above enrolled adults 55 and older at both doses, so there is direct efficacy and safety experience in this age group at the label doses. Age alone does not require dose adjustment, but older adults face higher fall risk from nighttime sedation, which is a reasonable factor to weigh before agreeing to escalate.

Comorbid depression or anxiety. Insomnia frequently coexists with mood and anxiety disorders. Longer-term extension data has been described in the literature as showing maintained efficacy without worsening mood in patients with comorbid depressive symptoms, though the exact study and its findings should be verified against the primary publication before being cited as a specific data point on this page. Any sleep medication carries a general caution to monitor mood and suicidal ideation, and this applies at either dose.

Shift workers and irregular schedules. The label's seven-hour sleep-window requirement is hard to meet with rotating or on-call schedules. Escalation decisions are more reliable once a patient has an established, consistent sleep window, since irregular timing makes it difficult to separate a drug effect from circadian misalignment.

When staying at 5 mg is the right call

The lower dose produced meaningful improvement in trial populations on its own. A patient who reports meaningfully better sleep with only minor residual complaints at 5 mg does not automatically need 10 mg; the incremental somnolence risk of the higher dose should be weighed against a real remaining symptom burden, not against a wish for a better score on paper. Patients who report morning drowsiness at 5 mg should not move to 10 mg until timing, food intake near the dose, and other sedating medications have been reviewed as possible causes.